Literature DB >> 12444918

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Miles D Houslay1, David R Adams.   

Abstract

cAMP is a second messenger that controls many key cellular functions. The only way to inactivate cAMP is to degrade it through the action of cAMP phosphodiesterases (PDEs). PDEs are thus poised to play a key regulatory role. PDE4 cAMP-specific phosphodiesterases appear to have specific functions with selective inhibitors serving as potent anti-inflammatory agents. The recent elucidation of the structure of the PDE4 catalytic unit allows for molecular insight into the mode of catalysis as well as substrate and inhibitor selectivity. The four PDE4 genes encode over 16 isoforms, each of which is characterized by a unique N-terminal region. PDE4 isoforms play a pivotal role in controlling functionally and spatially distinct pools of cAMP by virtue of their unique intracellular targeting. Targeting occurs by association with proteins, such as arrestins, SRC family tyrosyl kinases, A-kinase anchoring proteins ('AKAPs') and receptor for activated C kinase 1 ('RACK1'), and, in the case of isoform PDE4A1, by a specific interaction (TAPAS-1) with phosphatidic acid. PDE4 isoforms are 'designed' to be regulated by extracellular-signal-related protein kinase (ERK), which binds to anchor sites on the PDE4 catalytic domain that it phosphorylates. The upstream conserved region 1 (UCR1) and 2 (UCR2) modules that abut the PDE4 catalytic unit confer regulatory functions by orchestrating the functional outcome of phosphorylation by cAMP-dependent protein kinase ('PKA') and ERK. PDE4 enzymes stand at a crossroads that allows them to integrate various signalling pathways with that of cAMP in spatially distinct compartments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12444918      PMCID: PMC1223165          DOI: 10.1042/BJ20021698

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  127 in total

Review 1.  Protein modules and signalling networks.

Authors:  T Pawson
Journal:  Nature       Date:  1995-02-16       Impact factor: 49.962

2.  Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells.

Authors:  S Ghosh; J C Strum; V A Sciorra; L Daniel; R M Bell
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

3.  Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.

Authors:  I McPhee; L Pooley; M Lobban; G Bolger; M D Houslay
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

4.  Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected].

Authors:  Y M Horton; M Sullivan; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

5.  Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase.

Authors:  G Scotland; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

6.  Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by 1H NMR and identification of the membrane association domain using chimeric constructs.

Authors:  K J Smith; G Scotland; J Beattie; I P Trayer; M D Houslay
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

7.  Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation.

Authors:  C Sette; M Conti
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

8.  Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.

Authors:  Y Shakur; M Wilson; L Pooley; M Lobban; S L Griffiths; A M Campbell; J Beattie; C Daly; M D Houslay
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

9.  cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists.

Authors:  J Jurevicius; R Fischmeister
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells.

Authors:  M E DiSanto; K B Glaser; R J Heaslip
Journal:  Cell Signal       Date:  1995-11       Impact factor: 4.315

View more
  218 in total

1.  Association of PDE4B polymorphisms and schizophrenia in Northwestern Han Chinese.

Authors:  Fanglin Guan; Chen Zhang; Shuguang Wei; Hongbo Zhang; Xiaomin Gong; Jiali Feng; Chengge Gao; Rong Su; Huanming Yang; Shengbin Li
Journal:  Hum Genet       Date:  2011-12-11       Impact factor: 4.132

2.  Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options.

Authors:  Hakon Hakonarson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

3.  PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex.

Authors:  Jennifer J Carlisle Michel; Kimberly L Dodge; Wei Wong; Nicole C Mayer; Lorene K Langeberg; John D Scott
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

Review 4.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

5.  Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Authors:  Mahomi Kuroiwa; Gretchen L Snyder; Takahide Shuto; Atsuo Fukuda; Yuchio Yanagawa; David R Benavides; Angus C Nairn; James A Bibb; Paul Greengard; Akinori Nishi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

Review 6.  Genetics of stroke.

Authors:  Jin-min Guo; Ai-jun Liu; Ding-feng Su
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

7.  Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D.

Authors:  Hong Zhu; Hee Yun Suk; Raymond Y L Yu; Deborah Brancho; Opeyemi Olabisi; Teddy T C Yang; XiaoYong Yang; Jialin Zhang; Mustapha Moussaif; Jorge L Durand; Linda A Jelicks; Ja-Young Kim; Philipp E Scherer; Philippe G Frank; Michael P Lisanti; John W Calvert; Mark R Duranski; David J Lefer; Elaine Huston; George S Baillie; Miles D Houslay; Jeffrey D Molkentin; Jianping Jin; Chi-Wing Chow
Journal:  Mol Cell Biol       Date:  2010-07-20       Impact factor: 4.272

8.  New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.

Authors:  Sara Guariento; Olga Bruno; Paola Fossa; Elena Cichero
Journal:  Mol Divers       Date:  2015-08-20       Impact factor: 2.943

9.  Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.

Authors:  Ana Santos de Medeiros; Arlene R Wyman; Manal A Alaamery; Christina Allain; F Douglas Ivey; Lili Wang; Hai Le; James P Morken; Alawi Habara; Cuong Le; Shuaiying Cui; Adam Lerner; Charles S Hoffman
Journal:  Cell Signal       Date:  2017-09-01       Impact factor: 4.315

10.  Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.

Authors:  Han-Ting Zhang; Yu Zhao; Ying Huang; Chengjun Deng; Allen T Hopper; Michael De Vivo; Gregory M Rose; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2006-04-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.